Bristol-Myers Squibb (BMS) recently announced positive results from the Phase 2 PAISLEY study (NCT03252587) of the novel oral TYK2 inhibitor deucravicitinib in moderate-to-severe systemic lupus erythematosus (SLE) at the European Union of Rheumatology Association (EULAR) 2022 Congress. result. The data showed that the study met its primary endpoint of SRI-4 (SLE Responder Index 4) response at week 32 of treatment. SRI-4 is a composite endpoint used in SLE clinical trials to assess disease activity.

Pre: Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadelumab)

Next: 欧盟委员会授予ObsEva与Theramex联合开发的口服促性腺激素释放激素拮抗剂Yselty上市许可